지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.86 No.4
- 발행연도
- 2014.4
- 수록면
- 220 - 225 (6page)
이용수
초록· 키워드
오류제보하기
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. Several recent findings that there are activating mutations in the KIT and PDGFRA (platelet-derived growth factor receptor-α) genes of GISTs provide the rationale for using targeted therapies such as imatinib or sunitinib. Sunitinib, an oral multitargeted receptor tyrosine kinase inhibitor that inhibits kinases such as KIT, PDGFR (platelet-derived growth factor recepter), and VEGFR (vascular endothelial growth factor receptor), was recently approved for the treatment of imatinib-refractory GIST. Sunitinib is generally well tolerated and has an acceptable toxicity profile; an adverse event such as bowel perforation is rare. We present a patient with imatinib-refractory GIST who was successfully treated using sunitinib, but developed bowel perforation. The mechanism involved in bowel perforation associated with sunitinib is unknown. However, we presume that in our patient, the dramatic reduction in disseminated peritoneal metastases and bowel invasion of recurrent GIST during sunitinib treatment might have resulted in the bowel perforation.
목차
INTRODUCTION
CASE REPORT
DISCUSSION
REFERENCES
참고문헌 (10)
참고문헌 신청
1. [학술지(정기간행물)] - Rubin BP. / 2007 / Gas-rich MC, Corless CL. Gastrointestinal stromal tumour / Lancet 369 : 1731 ~ 1741
2. [학술지(정기간행물)] - Demetri GD. / 2002 / Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors / N Engl J Med 347 : 472 ~ 480
3. [학술지(정기간행물)] - Demetri GD. / 2006 / Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial / Lancet 368 : 1329 ~ 1338
4. [학술지(정기간행물)] - Rock EP. / 2007 / Food and Drug Administration drug approval summary : Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma / Oncologist 12 : 107 ~ 113
5. [학술지(정기간행물)] - Rutkowski P. / 2009 / Emergency surgery in the era of molecular treatment of solid tumours / Lancet Oncol 10 : 157 ~ 163
2. [학술지(정기간행물)] - Demetri GD. / 2002 / Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors / N Engl J Med 347 : 472 ~ 480
3. [학술지(정기간행물)] - Demetri GD. / 2006 / Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial / Lancet 368 : 1329 ~ 1338
4. [학술지(정기간행물)] - Rock EP. / 2007 / Food and Drug Administration drug approval summary : Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma / Oncologist 12 : 107 ~ 113
5. [학술지(정기간행물)] - Rutkowski P. / 2009 / Emergency surgery in the era of molecular treatment of solid tumours / Lancet Oncol 10 : 157 ~ 163
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2015-510-001432311